Allannic H, Lorcy Y, Leguerrier A M, Delambre C, Stetieh H, Madec A M, Orgiazzi J
Service de Médecine F, Hôpital Sud, Rennes.
Presse Med. 1991 Apr 13;20(14):645-6, 649-51.
We present the conclusions of two prospective studies of patients examined at their first manifestation of Graves' disease and treated with antithyroid drugs (ATD). The purpose of the first study was to investigate the effects of long-term treatment: the patients were given carbimazole in degressive doses without hormone replacement for 18 months, the followed up for 2 to 6 years after drug withdrawal. The second study was designed to determine the effect of treatment duration on the prognosis: the patients were given an ATD according to the same protocol for a duration randomly set at either 6 or 18 months, then seen again 2 years after ATD withdrawal. The results showed that after 18 months of treatment at least 50 percent of the patients could be expected to remain in remission for 6 years. Remissions were less frequent when treatment was shorter (41.7 percent after the 6 month treatment versus 61.8 percent after the 18 month treatment, with a 2 years' follow-up; P less than 0.05). The relapses that occurred came early: 70 percent of them took place within the first post-treatment month. This article also provides evidence of high T3 and/or T4 levels without signs of thyrotoxicosis during the post-treatment clinical course; these exclusively biochemical relapses spontaneously disappeared and may have been expressing epidoses of active thyroiditis.(ABSTRACT TRUNCATED AT 250 WORDS)
我们展示了两项前瞻性研究的结论,这些研究针对初次表现为格雷夫斯病并接受抗甲状腺药物(ATD)治疗的患者。第一项研究的目的是调查长期治疗的效果:患者接受递减剂量的卡比马唑治疗,为期18个月,且无激素替代,停药后随访2至6年。第二项研究旨在确定治疗时长对预后的影响:患者按照相同方案接受ATD治疗,治疗时长随机设定为6个月或18个月,停药2年后再次接受观察。结果显示,经过18个月的治疗,至少50%的患者有望维持6年的缓解期。治疗时间较短时缓解情况较少(6个月治疗后缓解率为41.7%,18个月治疗后为61.8%,随访2年;P<0.05)。复发出现得较早:70%的复发发生在治疗后的第一个月内。本文还提供了证据,表明在治疗后的临床过程中,患者存在高T3和/或T4水平但无甲状腺毒症迹象;这些仅为生化复发的情况会自发消失,可能表现为活动性甲状腺炎的发作。(摘要截断于250字)